Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Blended Water Supplies Impact Water Treatment

Where does my water come from? The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs. The New York City water…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Where does my water come from?

The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs.

The New York City water supply is a good example, providing over 1.2 billion gallons/day of domestic water to more than 8 million NYC residents, 1 million users from 4 upstate counties, and the city’s many visitors. The water system is made up of aqueducts, distribution pipes, reservoirs, and water tunnels offering a total system storage capacity of close to 550 billion gallons. There are three separate systems that bring water from upstate to the city to fit this need; the Croton, to the east of the Hudson River, and the Catskill and Delaware on the west.

What is in my water?

Since the opening of the Croton Water Filtration facility in May of 2015 water treatment professionals across the five boroughs have faced issues with a blended water supply. The neighborhoods of New York City often receive a combination of all three water supplies, the Croton, Catskill, and Delaware. Operational decisions about the City’s water supply, including the proportion of water from each of the systems, are often made on an hourly basis, creating a constantly changing chemistry of a building’s incoming water.

There is currently no formal notification system in place as to when a change in water supply might occur or what the blend could consist of. When Croton water is introduced to the system there could be areas within the same borough that are 100% Croton water or 100% Catskill/Delaware water, and others that are blended at varying percentages. Conductivity measurements are relied upon to gain an understanding of what water source you’re dealing with at each location throughout the city.

In general, the conductivity of the Catskill/Delaware supply is in the 90-100 µmho range while the conductivity of the Croton water is consistently in the 350-500 µmho range. For many facilities, when the make-up water has a conductivity greater than 100, it is assumed some level of blending is taking place. The chart below details some key differences in the inorganic chemistry of the water supplies:

How does this affect my water treatment?

From a water treatment perspective, fluctuating supply/makeup water sources present significant issues for system control. To understand this concept, it’s important to understand cycles of concentration (COC). Cooling tower cycles are typically controlled by the conductivity of the water in the system. When the conductivity reaches a predetermined set point, the controller bleeds water from the system and replaces it with fresh makeup water. The makeup water has a lower concentration of salts and dilutes the system water. With consistent makeup water, this control method is simple and quite effective because water treatment professionals can predict the levels of dissolved solids in the system water (important for inhibitor choice), determine hold times (the length of time the water stays in the system), and estimate water use.

Cooling tower treatment, for example, commonly bases the cycles of concentration calculation upon conductivity readings. The incoming city water conductivity is multiplied by the targeted number of cycles to use as the conductivity set point. Over-cycling could lead to issues with scale deposition when the concentration of dissolved solids gets above the saturation point. Under-cycling can lead to unnecessary water use, lower operational efficiency, and depending on control method, inaccurate inhibitor residuals. A constantly changing water supply makes it almost impossible to consistently maintain the targeted cycles for a specific system. This is particularly true when there is no way of knowing what type of water you could be receiving at a facility at any given time. Changing the chemistry of the makeup water also changes the target cycles. A varying water supply requires consistent on-site testing of the makeup water and an experienced water treatment professional to effectively manage the fluctuating conditions.

Chem-Aqua has the perfect blend of expertise and experience to manage your changing water demands. Contact a local representative today to review your water treatment program.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512